Methandriol


Methandriol, also known as methylandrostenediol, is an androgen and anabolic steroid medication which was developed by Organon and is used in both oral and injectable formulations. It is an orally active 17α-alkylated AAS and a derivative of the endogenous androgen prohormone androstenediol.

Medical uses

Methandriol has been used in the treatment of breast cancer in women. It has been reported to be almost as virilizing as comparable doses of testosterone propionate and methyltestosterone in women.

Available forms

Methandriol was previously marketed as 25 mL and 50 mg/mL aqueous suspensions for use by intramuscular injection.

Chemistry

Methandriol, also known as 17α-methyl-5-androstenediol or as 17α-methylandrost-5-ene-3β,17β-diol, is a synthetic androstane steroid and a 17α-alkylated derivative of 5-androstenediol. A number of esters of methandriol exist, including methandriol dipropionate, methandriol propionate, methandriol bisenanthoyl acetate, and methandriol diacetate. Methandriol is closely related to methyltestosterone.
An analogue of methandriol is its positional isomer methyl-4-androstenediol. Another analogue of methandriol is ethynylandrostanediol as well as its ester ethandrostate.

History

Methandriol was first synthesized in 1935 along with methyltestosterone and mestanolone.

Society and culture

Generic names

Methandriol is the generic name of methylandrostenediol and its.

Availability

Methandriol remains marketed for clinical use only in Taiwan and for veterinary use only in Australia.